Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 18/20 | 0.69 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.47 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1860141 | 0.88 | TRPV1 (0.53) | TRPV1MAOAKCNH2MAPK3ALDH1A1 | |
| SCHEMBL1862218 | 0.86 | TRPV1 (0.64) | TRPV1MAOAKCNH2MAPK3 | |
| SCHEMBL1865352 | 0.86 | TRPV1 (0.52) | TRPV1MAOAKCNH2MAPK3 | |
| SCHEMBL1856617 | 0.86 | TRPV1 (0.66) | TRPV1MAOAKCNH2MAPK3TEAD1 | |
| SCHEMBL1860849 | 0.82 | TRPV1 (1.00) | TRPV1MAOAKCNH2MAPK3 | |
| SCHEMBL12629702 | 0.81 | TRPV1 (0.64) | TRPV1MAOAKCNH2MAPK3TEAD1 | |
| SCHEMBL12629476 | 0.81 | TRPV1 (0.72) | TRPV1MAOAKCNH2MAPK3 | |
| SCHEMBL5113950 | 0.80 | TRPV1 (0.66) | TRPV1MAOAKCNH2MAPK3 | |
| SCHEMBL12664964 | 0.80 | TRPV1 (0.82) | TRPV1MAOAKCNH2MAPK3TEAD1 | |
| SCHEMBL5122130 | 0.80 | TRPV1 (0.68) | TRPV1MAOAKCNH2MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | PIGS, GPR52, GPR174 | TRPV1 549/4885MAOA 582/4885KCNH2 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.